Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-065729
Filing Date
2025-07-03
Accepted
2025-07-03 14:07:15
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10434
2 EXHIBIT I tm2519877d1_ex-1.htm EX-99.1 5834
  Complete submission text file 0001104659-25-065729.txt   18279
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Subject) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-45385 | Film No.: 251105016
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022
Business Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022 (212) 841-4100
INTEGRATED CORE STRATEGIES (US) LLC (Filed by) CIK: 0001319244 (see all company filings)

EIN.: 980330397 | Fiscal Year End: 1231
Type: SCHEDULE 13G